NCT06087354

Brief Summary

IVM with a pre-maturation step, known as capacitation IVM (CAPA-IVM), has demonstrated enhanced maturation of human oocytes in vitro and successful live births. However, CAPA-IVM has shown lower rates of embryo formation when compared to conventional in vitro fertilization/ intra cytoplasmic sperm injection (IVF/ICSI) cycles. To optimize the CAPA-IVM culture system, this pilot study aims to evaluate the impact of low oxygen versus air oxygen concentrations on embryological outcomes in PCOS patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 12, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 17, 2023

Completed
23 days until next milestone

Study Start

First participant enrolled

November 9, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 22, 2024

Completed
Last Updated

June 3, 2024

Status Verified

October 1, 2023

Enrollment Period

3 months

First QC Date

October 12, 2023

Last Update Submit

May 30, 2024

Conditions

Keywords

Low oxygenCAPA-IVMCumulus-oocyte complexes

Outcome Measures

Primary Outcomes (1)

  • Number of blastocyst

    Number of blastocyst obtained

    At least 5 days after intra-cytoplasmic sperm injection

Secondary Outcomes (12)

  • Number of matured oocytes

    Two days after oocytes pick-up

  • Number of normal fertilized oocytes

    16-18 hours after intra-cytoplasmic sperm injection

  • Number of day-3 embryos

    At least 3 days after intra-cytoplasmic sperm injection

  • Number of good-quality day-3 embryos

    At least 3 days after intra-cytoplasmic sperm injection

  • Number of good-quality blastocyst

    At least 5 days after intra-cytoplasmic sperm injection

  • +7 more secondary outcomes

Study Arms (2)

Low Oxygen Concentration CAPA-IVM culture

EXPERIMENTAL

Half of COCs were cultured in the CAPA step and IVM step in a low oxygen concentration (5%) and 6% carbon dioxide at 37 degree

Other: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition

Air Oxygen Concentration CAPA-IVM culture

EXPERIMENTAL

Half of COCs were cultured in the CAPA step and IVM step in a air oxygen concentration (20%) and 6% carbon dioxide at 37 degree

Other: The way of Cumulus-oocyte complexes (COC) CAPA-IVM culture condition

Interventions

Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM 24 hrs capacitation followed by 30h maturation. The first group will be cultured in low oxygen concentration (5%Oxygen), 6% carbon dioxide at 37 degree. The second group will be cultured in air oxygen concentration (20%Oxygen), 6% carbon dioxide at 37 degree.

Air Oxygen Concentration CAPA-IVM cultureLow Oxygen Concentration CAPA-IVM culture

Eligibility Criteria

Age18 Years - 37 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • ≤38 years
  • Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (\>10ml)
  • Having at least 20 follicles on the Oocyte Pick-up day
  • Patients consent to culture embryos to the blastocyst

You may not qualify if:

  • Cases with severe male factor (concentration \<5 million/ml, cryptozoospermia, azoospermia)
  • Oocyte donation
  • Pre-implantation genetic testing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

My Duc Hospital

Ho Chi Minh City, 70000, Vietnam

Location

Related Publications (5)

  • Sanchez F, Le AH, Ho VNA, Romero S, Van Ranst H, De Vos M, Gilchrist RB, Ho TM, Vuong LN, Smitz J. Biphasic in vitro maturation (CAPA-IVM) specifically improves the developmental capacity of oocytes from small antral follicles. J Assist Reprod Genet. 2019 Oct;36(10):2135-2144. doi: 10.1007/s10815-019-01551-5. Epub 2019 Aug 9.

    PMID: 31399916BACKGROUND
  • Vuong LN, Ho VNA, Ho TM, Dang VQ, Phung TH, Giang NH, Le AH, Pham TD, Wang R, Smitz J, Gilchrist RB, Norman RJ, Mol BW. In-vitro maturation of oocytes versus conventional IVF in women with infertility and a high antral follicle count: a randomized non-inferiority controlled trial. Hum Reprod. 2020 Nov 1;35(11):2537-2547. doi: 10.1093/humrep/deaa240.

    PMID: 32974672BACKGROUND
  • Vuong LN, Le AH, Ho VNA, Pham TD, Sanchez F, Romero S, De Vos M, Ho TM, Gilchrist RB, Smitz J. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020 Feb;37(2):347-357. doi: 10.1007/s10815-019-01677-6. Epub 2020 Jan 4.

    PMID: 31902102BACKGROUND
  • Preis KA, Seidel GE Jr, Gardner DK. Reduced oxygen concentration improves the developmental competence of mouse oocytes following in vitro maturation. Mol Reprod Dev. 2007 Jul;74(7):893-903. doi: 10.1002/mrd.20655.

    PMID: 17192892BACKGROUND
  • Akin N, Ates G, von Mengden L, Herta AC, Meriggioli C, Billooye K, Stocker WA, Ghesquiere B, Harrison CA, Cools W, Klamt F, Massie A, Smitz J, Anckaert E. Effects of lactate, super-GDF9, and low oxygen tension during bi-phasic in vitro maturation on the bioenergetic profiles of mouse cumulus-oocyte complexdagger. Biol Reprod. 2023 Oct 13;109(4):432-449. doi: 10.1093/biolre/ioad085.

    PMID: 37531262BACKGROUND

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian CystsCystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Study Officials

  • Tuong M Ho

    Mỹ Đức Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 12, 2023

First Posted

October 17, 2023

Study Start

November 9, 2023

Primary Completion

January 30, 2024

Study Completion

May 22, 2024

Last Updated

June 3, 2024

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations